Cerebellar atrophy in a child with valproate toxicity.
In the treatment of epilepsy, selecting an appropriate antiepileptic drug for each individual patient requires matching the patient's clinical needs with the agent's specific pharmacological attributes. In many situations, the final choice of an antiepileptic drug may need a change due to the agent's side-effect profile. The authors report a ten-year-old child with Lennox Gastaut syndrome who developed recurrence of seizures, hyperammonemic encephalopathy and cerebellar atrophy on valproate therapy. Valproate was discontinued and lamotrigine was added followed by good control of seizures. Cerebellar atrophy as a serious adverse side effect of valproate therapy, has been infrequently reported.
Department of Pediatrics, MAMC & Associated Lok Nayak Hospital, New Delhi, India.
Vidya B
VB
Ghosh
Seema
S
Kapoor
Anjali
A
Prakash
Sinchana
S
Bhatt
D000927:Anticonvulsants / Q000009:adverse effects*; D001284:Atrophy / Q000139:chemically induced; D002531:Cerebellum / Q000473:pathology*; D002648:Child; D006801:Humans; D022124:Hyperammonemia / Q000139:chemically induced*; D008297:Male; D014635:Valproic Acid / Q000009:adverse effects*
D000927:Anticonvulsants; D014635:Valproic Acid
Epilepsia. 1997 Dec;38(12):1283-8
9578523
Neurol India. 2005 Jun;53(2):226-8
16010067
Epilepsia. 1998 Jan;39(1):27-32
9578009
Epilepsia. 2009 May;50(5):1158-66
19170737
Metab Brain Dis. 2002 Dec;17(4):367-73
12602513
Ann Neurol. 1995 Oct;38(4):687-91
7574471
Indian J Pediatr. 2003 Feb;70(2):147-51
12661810
Can J Neurol Sci. 1987 Aug;14(3):294-6
3117347
Indian J Pediatr. 1996 Mar-Apr;63(2):233-41
10829995